{"id":"NCT03473977","sponsor":"Children's Hospital Medical Center, Cincinnati","briefTitle":"Benralizumab for Eosinophilic Gastritis (BEGS)","officialTitle":"A Randomized, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-04-23","primaryCompletion":"2020-06-22","completion":"2022-01-12","firstPosted":"2018-03-22","resultsPosted":"2021-08-17","lastUpdate":"2022-02-03"},"enrollment":26,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Gastritis or Gastroenteritis"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":["Fasenra"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Benralizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis.","primaryOutcome":{"measure":"Percent of Patients in Histological Remission (<30 Eos/Hpf)","timeFrame":"12 weeks after start of treatment","effectByArm":[{"arm":"Benralizumab","deltaMin":77,"sd":null},{"arm":"Placebo","deltaMin":8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":15},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37336228"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Headache","Vomiting","Abdominal Pain","Dizziness","Anemia"]}}